CoChat

Serum neurofilament light as a biomarker in progressive multiple sclerosis

Open access
Kapoor, Raju, Smith, Kathryn E., Allegretta, Mark, Arnold, Douglas L., Carroll, William, Comabella, Manuel, Furlan, Roberto, Harp, Christopher, Kuhle, Jens, Leppert, David, Plavina, Tatiana, Sellebjerg, Finn, Sincock, Caroline, Teunissen, Charlotte E., Topalli, Ilir, von Raison, Florian, Walker, Elizabeth, Fox, Robert J. · 2020 · Neurology
Cited by 156

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the International Progressive MS Alliance convened a standing expert panel to consider potential tissue fluid biomarkers in MS in general and in progressive MS specifically. The panel focused their attention on neurofilament light chain (NfL) in serum or plasma, examining data from both relapsing and progressive MS. Here, we report the initial conclusions of the panel and its recommendations for further research. Serum NfL (sNfL) is a plausible marker of neurodegeneration that can be measured accurately, sensitively, and reproducibly, but standard procedures for sample processing and analysis should be established. Findings from relapsing and progressive cohorts concur and indicate that sNfL concentrations correlate with imaging and disability measures, predict the future course of the disease, and can predict response to treatment. Importantly, disease activity from active inflammation (i.e., new T2 and gadolinium-enhancing lesions) is a large contributor to sNfL, so teasing apart disease activity from the disease progression that drives insidious disability progression in progressive MS will be challenging. More data are required on the effects of age and comorbidities, as well as the relative contributions of inflammatory activity and other disease processes. The International Progressive MS Alliance is well positioned to advance these initiatives by connecting and supporting relevant stakeholders in progressive MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000010346

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 156

Metadata

Authors
Kapoor, R., Smith, K. E., Allegretta, M., Arnold, D. L., Carroll, W., Comabella, M., Furlan, R., Harp, C., Kuhle, J., Leppert, D., Plavina, T., Sellebjerg, F., Sincock, C., Teunissen, C. E., Topalli, I., von Raison, F., Walker, E., & Fox, R. J.
Venue
Neurology
Published
2020-09-08
Volume
95
Issue
10
Pages
436-444
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3042931334
Cited by
156
References
13
FWCI
14.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum neurofilament light as a biomarker in progressive multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.0000000000010346
The paper
Kapoor, R., Smith, K. E., Allegretta, M., Arnold, D. L., Carroll, W., Comabella, M., Furlan, R., Harp, C., Kuhle, J., Leppert, D., Plavina, T., Sellebjerg, F., Sincock, C., Teunissen, C. E., Topalli, I., von Raison, F., Walker, E., & Fox, R. J. (2020). Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.0000000000010346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.